Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1
Status:
COMPLETED
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The study should evaluate the biological distribution of \[123I\]I-DARPIN-Ec1 in patients with lung and ovarian cancer
The primary objective are:
1. To assess the distribution of \[123I\]I-DARPIN-Ec1 in normal tissues and tumors at different time intervals.
2. To evaluate dosimetry of \[123I\]I-DARPIN-Ec1.
3. To study the safety and tolerability of the drug \[123I\]I-DARPIN-Ec1 after a single injection in a diagnostic dosage.
The secondary objective are:
1\. To compare the obtained \[123I\]I-DARPIN-Ec1 SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in lung and ovarian cancer patients.
Phase:
PHASE1
Details
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences
Collaborators:
The Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry Uppsala University